Advertisement

A new approach for anemia in kidney disease

Published:November 26, 2019DOI:https://doi.org/10.1016/j.ejim.2019.10.035
      Anemia represents an almost obligatory complication in patients with chronic kidney disease (CKD) and, if ineffectively treated, is associated with increased cardiovascular (CV) mortality, a reduced quality of life and the well know clinical consequences secondary to the need of an exceedingly high number of iron infusions and red blood cell (RBC) transfusions, which have been the only available therapy until the end of 1980s [
      • Hsu C.Y.
      • McCulloch C.E.
      • Curhan G.C.
      Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey.
      ,
      • Shah R.
      • Agarwal A.K.
      Anemia associated with chronic heart failure: current concepts.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hsu C.Y.
        • McCulloch C.E.
        • Curhan G.C.
        Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey.
        J Am Soc Nephrol. 2002; 13 (PubMed PMID: 11805181): 504-510
        • Shah R.
        • Agarwal A.K.
        Anemia associated with chronic heart failure: current concepts.
        Clin Interv Aging. 2013; 8 (Epub 2013 Feb 4. Review. PubMed PMID: 23403618; PubMed Central PMCID: PMC3569049): 111-122https://doi.org/10.2147/CIA.S27105
        • Locatelli F.
        • Del Vecchio L.
        An expert opinion on the current treatment of anemia in patients with kidney disease.
        Expert Opin Pharmacother. 2012; 13 (Epub 2012 Feb 2. Review. PubMed PMID: 22296648): 495-503https://doi.org/10.1517/14656566.2012.658369
        • Singh A.K.
        • Szczech L.
        • Tang K.L.
        • Barnhart H.
        • Sapp S.
        • Wolfson M.
        • Reddan D.
        • CHOIR Investigators
        Correction of anemia with epoetin alfa in chronic kidney disease.
        N Engl J Med. 2006 Nov 16; 355 (PubMed PMID: 17108343): 2085-2098
        • Drüeke T.B.
        • Locatelli F.
        • Clyne N.
        • Eckardt K.U.
        • Macdougall I.C.
        • Tsakiris D.
        • Burger H.U.
        • Scherhag A.
        • CREATE Investigators
        Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
        N Engl J Med. 2006 Nov 16; 355 (PubMed PMID: 17108342): 2071-2084
        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • Cooper M.E.
        • de Zeeuw D.
        • Eckardt K.U.
        • Feyzi J.M.
        • Ivanovich P.
        • Kewalramani R.
        • Levey A.S.
        • Lewis E.F.
        • McGill J.B.
        • McMurray J.J.
        • Parfrey P.
        • Parving H.H.
        • Remuzzi G.
        • Singh A.K.
        • Solomon S.D.
        • Toto R.
        • TREAT Investigators
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009 Nov 19; 361 (Epub 2009 Oct 30. PubMed PMID: 19880844): 2019-2032https://doi.org/10.1056/NEJMoa0907845
        • Kapitsinou P.P.
        • Liu Q.
        • Unger T.L.
        • Rha J.
        • Davidoff O.
        • Keith B.
        • Epstein J.A.
        • Moores S.L.
        • Erickson-Miller C.L.
        • Haase V.H.
        Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.
        Blood. 2010 Oct 21; 116 (Epub 2010 Jul 13. PubMed PMID: 20628150; PubMed Central PMCID: PMC2974609): 3039-3048https://doi.org/10.1182/blood-2010-02-270322
        • Sanghani N.S.
        • Haase V.H.
        Hypoxia-inducible factor activators in renal anemia: current clinical experience.
        Adv Chronic Kidney Dis. 2019; 26 (Review. PubMed PMID: 31477256): 253-266https://doi.org/10.1053/j.ackd.2019.04.004
        • Besarab A.
        • Provenzano R.
        • Hertel J.
        • Zabaneh R.
        • Klaus S.J.
        • Lee T.
        • Leong R.
        • Hemmerich S.
        • Yu K.H.
        • Neff T.B.
        Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
        Nephrol Dial Transplant. 2015; 30 (Epub 2015 Aug 3. PubMed PMID: 26238121; PubMed Central PMCID: PMC4569392): 1665-1673https://doi.org/10.1093/ndt/gfv302
        • Provenzano R.
        • Besarab A.
        • Wright S.
        • Dua S.
        • Zeig S.
        • Nguyen P.
        • Poole L.
        • Saikali K.G.
        • Saha G.
        • Hemmerich S.
        • Szczech L.
        • Yu K.H.
        • Neff T.B.
        Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study.
        Am J Kidney Dis. 2016; 67 (Epub 2016 Feb 2. PubMed PMID: 26846333): 912-924https://doi.org/10.1053/j.ajkd.2015.12.020
        • Chen N.
        • Qian J.
        • Chen J.
        • Yu X.
        • Mei C.
        • Hao C.
        • Jiang G.
        • Lin H.
        • Zhang X.
        • Zuo L.
        • He Q.
        • Fu P.
        • Li X.
        • Ni D.
        • Hemmerich S.
        • Liu C.
        • Szczech L.
        • Besarab A.
        • Neff T.B.
        • Peony Yu K.H.
        • Valone F.H.
        Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
        Nephrol Dial Transplant. 2017; 32 (PubMed PMID: 28371815; PubMed Central PMCID: PMC5837707): 1373-1386https://doi.org/10.1093/ndt/gfx011
        • Chen N.
        • Hao C.
        • Liu B.C.
        • Lin H.
        • Wang C.
        • Xing C.
        • Liang X.
        • Jiang G.
        • Liu Z.
        • Li X.
        • Zuo L.
        • Luo L.
        • Wang J.
        • Zhao M.H.
        • Liu Z.
        • Cai G.Y.
        • Hao L.
        • Leong R.
        • Wang C.
        • Liu C.
        • Neff T.
        • Szczech L.
        • Yu K.P.
        Roxadustat treatment for anemia in patients undergoing long-term dialysis.
        N Engl J Med. 2019; 381 (Epub 2019 Jul 24. PubMed PMID: 31340116): 1011-1022https://doi.org/10.1056/NEJMoa1901713
        • Chen N.
        • Hao C.
        • Peng X.
        • Lin H.
        • Yin A.
        • Hao L.
        • Tao Y.
        • Liang X.
        • Liu Z.
        • Xing C.
        • Chen J.
        • Luo L.
        • Zuo L.
        • Liao Y.
        • Liu B.C.
        • Leong R.
        • Wang C.
        • Liu C.
        • Neff T.
        • Szczech L.
        • Yu K.P.
        Roxadustat for anemia in patients with kidney disease not receiving dialysis.
        N Engl J Med. 2019; 381 (Epub 2019 Jul 24. PubMed PMID: 31340089): 1001-1010https://doi.org/10.1056/NEJMoa1813599
        • Jain I.H.
        • Zazzeron L.
        • Goli R.
        • Alexa K.
        • Schatzman-Bone S.
        • Dhillon H.
        • Goldberger O.
        • Peng J.
        • Shalem O.
        • Sanjana N.E.
        • Zhang F.
        • Goessling W.
        • Zapol W.M.
        • Mootha V.K.
        Hypoxia as a therapy for mitochondrial disease.
        Science. 2016; 352 (Epub 2016 Feb 25. PubMed PMID: 26917594; PubMed Central PMCID: PMC4860742): 54-61https://doi.org/10.1126/science.aad9642
        • Besarab A.
        • Chernyavskaya E.
        • Motylev I.
        • Shutov E.
        • Kumbar L.M.
        • Gurevich K.
        • Chan D.T.
        • Leong R.
        • Poole L.
        • Zhong M.
        • Saikali K.G.
        • Franco M.
        • Hemmerich S.
        • Yu K.H.
        • Neff T.B.
        Roxadustat (FG-4592): correction of anemia in incident dialysis patients.
        J Am Soc Nephrol. 2016; 27 (Epub 2015 Oct 22. PubMed PMID: 26494833; PubMed Central PMCID: PMC4814189): 1225-1233https://doi.org/10.1681/ASN.2015030241
        • Tang D.
        • Zhang J.
        • Yan T.
        • Wei J.
        • Jiang X.
        • Zhang D.
        • Zhang Q.
        • Jia J.
        • Huang Y.
        FG-4592 accelerates cutaneous wound healing by epidermal stem cell activation via HIF-1α stabilization.
        Cell Physiol Biochem. 2018; 46 (Epub 2018 May 5. PubMed PMID: 29742498): 2460-2470https://doi.org/10.1159/000489652
        • Zhang P.
        • Du J.
        • Zhao H.
        • Cheng Y.
        • Dong S.
        • Yang Y.
        • Li B.
        • Gao F.
        • Sun X.
        • Cai J.
        • Liu C.
        Radioprotective effects of roxadustat (FG-4592) in haematopoietic system.
        J Cell Mol Med. 2019; 23 (Epub 2018 Oct 18. PubMed PMID: 30334352; PubMed Central PMCID: PMC6307774): 349-356https://doi.org/10.1111/jcmm.13937
        • Li X.
        • Cui X.X.
        • Chen Y.J.
        • Wu T.T.
        • Xu H.
        • Yin H.
        • Wu Y.C.
        Therapeutic potential of a prolyl hydroxylase inhibitor FG-4592 for Parkinson's diseases in vitro and in vivo: regulation of redox biology and mitochondrial function.
        Front Aging Neurosci. 2018; 10 (eCollection 2018. PubMed PMID: 29755339; PubMed Central PMCID: PMC5935184): 121https://doi.org/10.3389/fnagi.2018.00121
        • Xie R.Y.
        • Fang X.L.
        • Zheng X.B.
        • Lv W.Z.
        • Li Y.J.
        • Ibrahim Rage H.
        • He Q.L.
        • Zhu W.P.
        • Cui T.X.
        Salidroside and FG-4592 ameliorate high glucose-induced glomerular endothelial cells injury via HIF upregulation.
        Biomed Pharmacother. 2019; 118 ([Epub ahead of print] PubMed PMID: 31351423)109175https://doi.org/10.1016/j.biopha.2019.109175
        • Mokas S.
        • Larivière R.
        • Lamalice L.
        • Gobeil S.
        • Cornfield D.N.
        • Agharazii M.
        • Richard D.E.
        Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification.
        Kidney Int. 2016; 90 (Epub 2016 Jul 26. PubMed PMID: 27470678): 598-609https://doi.org/10.1016/j.kint.2016.05.020
        • ygulska K.
        • Wejner-Mik P.
        • Plewka M.
        • Figiel Ł.
        • Chrzanowski Ł.
        • Kasprzak J.D.
        Roxadustat: another drug that causes pulmonary hypertension? Report of first human case.
        Pol Arch Intern Med. 2019; 129 (Epub 2019 Feb 13. PubMed PMID: 30758318): 344-345https://doi.org/10.20452/pamw.4445
        • Groenendaal-van de Meent D.
        • Adel M.D.
        • Noukens J.
        • Rijnders S.
        • Krebs-Brown A.
        • Mateva L.
        • Alexiev A.
        • Schaddelee M.
        Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
        Clin Drug Investig. 2016; 36 (PubMed PMID: 27352308; PubMed Central PMCID: PMC4987405): 743-751https://doi.org/10.1007/s40261-016-0422-y
        • Del Vecchio L.
        • Locatelli F.
        Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
        Expert Opin Investig Drugs. 2018; 27 (Epub 2018 Jul 12. Review. PubMed PMID: 29975110): 613-621https://doi.org/10.1080/13543784.2018.1493455
        • Li W.
        • Zhao Y.
        • Fu P.
        Hypoxia induced factor in chronic kidney disease: friend or foe?.
        Front Med (Lausanne). 2018; 4 (eCollection 2017. PubMed PMID: 29404328; PubMed Central PMCID: PMC5786558): 259https://doi.org/10.3389/fmed.2017.00259
        • Schley G.
        • Klanke B.
        • Kalucka J.
        • Schatz V.
        • Daniel C.
        • Mayer M.
        • Goppelt-Struebe M.
        • Herrmann M.
        • Thorsteinsdottir M.
        • Palsson R.
        • Beneke A.
        • Katschinski D.M.
        • Burzlaff N.
        • Eckardt K.U.
        • Weidemann A.
        • Jantsch J.
        • Willam C.
        Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
        Kidney Int. 2019; 96 (Epub 2019 Mar 5. PubMed PMID: 31146971): 378-396https://doi.org/10.1016/j.kint.2019.02.016
        • Krock B.L.
        • Skuli N.
        • Simon M.C.
        Hypoxia-induced angiogenesis: good and evil.
        Genes Cancer. 2011; 2 (PubMed PMID: 22866203; PubMed Central PMCID: PMC3411127): 1117-1133https://doi.org/10.1177/1947601911423654
        • Price C.
        • Gill S.
        • Ho Z.V.
        • Davidson S.M.
        • Merkel E.
        • McFarland J.M.
        • Leung L.
        • Tang A.
        • Kost-Alimova M.
        • Tsherniak A.
        • Jonas O.
        • Vazquez F.
        • Hahn W.C.
        Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
        Cancer Res. 2019; 79 (Epub 2019 Mar 21. PubMed PMID: 30898838; PubMed Central PMCID: PMC6522283): 2564-2579https://doi.org/10.1158/0008-5472.CAN-18-2674
        • Fujimoto T.N.
        • Colbert L.E.
        • Huang Y.
        • Molkentine J.M.
        • Deorukhkar A.
        • Baseler L.
        • de la Cruz Bonilla M.
        • Yu M.
        • Lin D.
        • Gupta S.
        • Cabeceiras P.K.
        • Kingsley C.V.
        • Tailor R.C.
        • Sawakuchi G.O.
        • Koay E.J.
        • Piwnica-Worms H.
        • Maitra A.
        • Taniguchi C.M.
        Selective EGLN inhibition enables ablative radiotherapy and improves survival in unresectable pancreatic cancer.
        Cancer Res. 2019; 79 (PubMed PMID: 31043430; PubMed Central PMCID: PMC6666414): 2327-2338https://doi.org/10.1158/0008-5472.CAN-18-1785